Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease
- PMID: 12897209
- PMCID: PMC166296
- DOI: 10.1172/JCI18104
Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease
Abstract
Alzheimer disease (AD) is characterized by the progressive deposition of the 42-residue amyloid beta protein (Abeta) in brain regions serving memory and cognition. In animal models of AD, immunization with Abeta results in the clearance of Abeta deposits from the brain. However, a trial of vaccination with synthetic human Abeta1-42 in AD resulted in the development of meningoencephalitis in some patients. We measured cellular immune responses to Abeta in middle-aged and elderly healthy subjects and in patients with AD. A significantly higher proportion of healthy elderly subjects and patients with AD had strong Abeta-reactive T cell responses than occurred in middle-aged adults. The immunodominant Abeta epitopes in humans resided in amino acids 16-33. Epitope mapping enabled the identification of MHC/T cell receptor (TCR) contact residues. The occurrence of intrinsic T cell reactivity to the self-antigen Abeta in humans has implications for the design of Abeta vaccines, may itself be linked to AD susceptibility and course, and appears to be associated with the aging process.
Figures
Comment in
-
Amyloid beta and Alzheimer disease therapeutics: the devil may be in the details.J Clin Invest. 2003 Aug;112(3):321-3. doi: 10.1172/JCI19420. J Clin Invest. 2003. PMID: 12897198 Free PMC article.
Similar articles
-
Strikingly reduced amyloid burden and improved behavioral performance in Alzheimer's disease mice immunized with recombinant chimeric vaccines by hexavalent foldable Aβ₁₋₁₅ fused to toxin-derived carrier proteins.J Alzheimers Dis. 2014;41(1):243-60. doi: 10.3233/JAD-132177. J Alzheimers Dis. 2014. PMID: 24625800
-
Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide.J Immunol. 2005 Feb 1;174(3):1580-6. doi: 10.4049/jimmunol.174.3.1580. J Immunol. 2005. PMID: 15661919
-
Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease.Immunol Lett. 2007 Sep 15;112(1):30-8. doi: 10.1016/j.imlet.2007.06.006. Epub 2007 Jul 23. Immunol Lett. 2007. PMID: 17686533 Free PMC article.
-
Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans.Rejuvenation Res. 2006 Spring;9(1):77-84. doi: 10.1089/rej.2006.9.77. Rejuvenation Res. 2006. PMID: 16608400 Review.
-
Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.Immunotherapy. 2012 Feb;4(2):213-38. doi: 10.2217/imt.11.170. Immunotherapy. 2012. PMID: 22339463 Review.
Cited by
-
Promoted CD4+ T cell-derived IFN-γ/IL-10 by photobiomodulation therapy modulates neurogenesis to ameliorate cognitive deficits in APP/PS1 and 3xTg-AD mice.J Neuroinflammation. 2022 Oct 10;19(1):253. doi: 10.1186/s12974-022-02617-5. J Neuroinflammation. 2022. PMID: 36217178 Free PMC article.
-
Immune effects of optimized DNA vaccine and protective effects in a MPTP model of Parkinson's disease.Neurol Sci. 2013 Sep;34(9):1559-70. doi: 10.1007/s10072-012-1284-6. Epub 2013 Jan 25. Neurol Sci. 2013. PMID: 23354599
-
Microbial amyloids in neurodegenerative amyloid diseases.FEBS J. 2023 Dec 2:10.1111/febs.17023. doi: 10.1111/febs.17023. Online ahead of print. FEBS J. 2023. PMID: 38041542 Review.
-
Can peripheral leukocytes be used as Alzheimer's disease biomarkers?Expert Rev Neurother. 2009 Nov;9(11):1623-33. doi: 10.1586/ern.09.118. Expert Rev Neurother. 2009. PMID: 19903022 Free PMC article. Review.
-
An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives.J Neurosci. 2004 Jul 14;24(28):6277-82. doi: 10.1523/JNEUROSCI.1344-04.2004. J Neurosci. 2004. PMID: 15254082 Free PMC article.
References
-
- Price DL, Sisodia SS. Mutant genes in familial Alzheimer’s disease and transgenic models. Annu. Rev. Neurosci. 1998;21:479–505. - PubMed
-
- Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol. Rev. 2001;81:741–766. - PubMed
-
- Jarrett JT, Lansbury PT., Jr Seeding “one-dimensional crystallization” of amyloid: a pathogenic mechanism in Alzheimer’s disease and scrapie? Cell. 1993;73:1055–1058. - PubMed
-
- McGeer EG, McGeer PL. The importance of inflammatory mechanisms in Alzheimer disease. Exp. Gerontol. 1998;33:371–378. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials